Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40microg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG in Plasma Donors Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs Botulism vaccine (Primary)
- Indications Botulism
- Focus Pharmacodynamics
- 28 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 27 Jul 2015 Planned End Date changed from 1 Dec 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 27 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.